This article is more than 5 years old. Information may no longer be current.

Hydrus microstent yields lower IOP, rapid visual recovery

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Two-year results of the HORIZON study showed phacoemulsification combined with a Hydrus microstent significantly lowered IOP compared with phacoemulsification alone, according to a speaker here. In addition, patients who received the Hydrus were statistically more likely to remain medication-free.

“Hydrus-treated eyes had rapid visual recovery with 94% 20/40 or better after 1 week and 98% 20/40 or better after 1 month. The Hydrus study arm had fewer IOP spikes and required less subsequent glaucoma surgery compared to cataract surgery alone,” Thomas W. Samuelson, MD, said at the American Glaucoma Society annual meeting.

The HORIZON study included 556 patients with mild to moderate primary open-angle glaucoma randomized to cataract surgery alone or cataract surgery with the Hydrus (Ivantis).

At 24 months, 77.2% of patients in the Hydrus arm of the study experienced a 20% reduction in diurnal IOP compared with 57.8% of patients in the cataract surgery-alone arm.

“The Hydrus implantation significantly added to IOP reduction from phacoemulsification, and importantly the treatment effect is maintained throughout the 2-year study period, just as robust at 2 years as it is at 1 year,” Samuelson said. – by Robert Linnehan

Reference:

Samuelson TW. HORIZON. Results from the prospective, multicenter randomized trial of the Hydrus microstent. Presented at American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.

Disclosure: Samuelson reports he is a consultant for AcuMems, Aerie Pharmaceutical, Akorn, Alcon Surgical, Abbott Medical Optics, AqueSys, Allergan, Bausch + Lomb, Belkin Laser, Endo Optiks, Glaukos, Equinox, Ivantis, Ocular Surgery News, PolyActiva, Santen, Shire, Transcend Medical and Veracity Innovation.